TMEM106Bregulates progranulin levels and the penetrance of FTLD in GRNmutation carriers(e–Pub ahead of print)

Authors :: Finch, N.
Carrasquillo, M.M.
Baker, M.
Rutherford, N.J.
Coppola, G.
DeJesus-Hernandez, M.
Crook, R.
Hunter, T.
Ghidoni, R.
Benussi, L.
Crook, J.
Finger, E.
Hantanpaa, K.J.
Karydas, A.M.
Sengdy, P.
Gonzalez, J.
Seeley, W.W.
Johnson, N.
Beach, T.G.
Mesulam, M.
Forloni, G.
Kertesz, A.
Knopman, D.S.
Uitti, R.
White, C.L.
Caselli, R.
Lippa, C.
Bigio, E.H.
Wszolek, Z.K.
Binetti, G.
Mackenzie, I.R.
Miller, B.L.
Boeve, B.F.
Younkin, S.G.
Dickson, D.W.
Petersen, R.C.
Graff-Radford, N.R.
Geschwind, D.H.
Rademakers, R.
Source :: Neurology (Ovid); February 2011, Vol. 76 Issue: 5 p467-474, 8p
Publication Year :: 2011
Abstract: To determine whether TMEM106Bsingle nucleotide polymorphisms (SNPs) are associated with frontotemporal lobar degeneration (FTLD) in patients with and without mutations in progranulin (GRN) and to determine whether TMEM106Bmodulates GRNexpression.

Full Text Access

Tools